Moderna to Present Five Abstracts at 2025 Metabolism Congress
Moderna, Inc. has announced that five abstracts detailing its investigational mRNA therapeutics will be presented at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM). The congress is scheduled to take place from September 2-6, 2025, at the Kyoto International Conference Center in Kyoto, Japan. This marks a significant milestone for the company, as it will be the first occasion that data related to methylmalonic acidemia (MMA) and Glycogen Storage Disease Type 1a (GSD1a) will be shared at a scientific congress.
Among the accepted abstracts, three will be presented orally while two will be displayed as posters. The presentations will focus on Moderna’s ongoing research into these rare metabolic disorders, specifically addressing the company’s efforts in the areas of propionic acidemia (PA), MMA, and GSD1a.
Details of the Presentations
The specific details regarding the presentations will be made available as the congress approaches. Participants and attendees can expect insights into the latest developments in mRNA therapeutic approaches targeting these conditions. This scientific gathering serves as a platform for researchers, clinicians, and industry professionals to exchange knowledge and discuss advancements in the field of metabolic disorders.
The inclusion of Moderna’s research at this international venue underscores the company’s commitment to addressing rare genetic diseases through innovative therapeutic solutions. With the potential to significantly impact patient care, the data presented at ICIEM may pave the way for future advancements in treatment methodologies.
As Moderna continues to expand its portfolio beyond COVID-19 vaccines, the focus on rare diseases reflects a broader strategy aimed at leveraging its mRNA technology to develop therapies for conditions that currently have limited treatment options.
The upcoming congress will be an important event for stakeholders in the field, and Moderna’s participation highlights the growing significance of mRNA therapeutics in addressing complex health challenges.
